Eutilex picks up $18.9 mln Series A

Seoul, South Korea-based Eutilex Co Ltd, an biopharmaceutical company focused on treating cancers and autoimmune diseases, has closed $18.9 million in Series A financing. The investors included DS Asset Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel.

North AmericaUSBriefs